CJC-1295 vs Modified GRF 1-29: GHRH Peptide Comparison for Growth Hormone Research

Research comparison of CJC-1295 with DAC (long-acting, GH bleed) vs Modified GRF 1-29 (short-acting, pulsatile GH release) — mechanism differences, dosing protocols, pulsatility importance, and why MOD GRF + Ipamorelin is the gold standard GH research stack.

TL;DR

• Modified GRF 1-29: half-life ~30 min, pulsatile GH release, 100-300mcg per dose, 1-2x daily
• CJC-1295 with DAC: half-life ~8 days, sustained GH elevation ("bleed"), 1-2mg once weekly
• MOD GRF 1-29 + Ipamorelin (both 100-300mcg) is the most physiological GH research protocol
• CJC-DAC may impair long-term pituitary sensitivity due to continuous GH stimulation

Disclaimer: For educational and research purposes only — not medical advice.

Growth hormone-releasing hormone (GHRH) analogs form one half of the classic GH secretagogue research stack. The two dominant GHRH peptides in use — Modified GRF 1-29 and CJC-1295 with DAC — share the same receptor target but have dramatically different pharmacokinetic profiles with meaningful implications for how they affect the GH axis.

The GHRH Family Tree

Native GHRH (Somatocrinin): 44 amino acids; full-length endogenous hormone; very short half-life (~5 min); not commercially practical

Sermorelin: First 29 amino acids of GHRH (GHRH 1-29); half-life ~12 minutes; used in Geref (discontinued); available from compounders

Modified GRF 1-29 (MOD GRF 1-29): Sermorelin with 4 stabilizing amino acid substitutions (at positions 2, 8, 15, 27); half-life ~30 minutes; the current research standard for pulsatile GH research

CJC-1295 without DAC: Another name for Modified GRF 1-29 — the same compound; causes naming confusion in the community

CJC-1295 with DAC: Modified GRF 1-29 with an additional reactive group that forms a covalent bond with lysine residues on albumin (the Drug Affinity Complex = DAC); half-life ~8 days; creates "GH bleed"

Modified GRF 1-29: The Physiological Choice

Half-life: ~30 minutes after SubQ injection (some variance)

GH release pattern: Creates a discrete, high-amplitude GH pulse that resolves within 2-4 hours. When taken 1-2x daily, there are substantial trough periods where no GHRH is signaling — preserving somatotroph sensitivity.

Mechanism of pulsatility preservation:

1. GH secreting cells (somatotrophs) require trough periods to resensitize
2. Sustained GHRH → continuous GH production → downregulation of GHRH receptors → blunted response over time
3. MOD GRF's short half-life allows resensitization between doses

Best for: Researchers who inject 1-2x daily and want physiological GH pulsatility, maximal GH pulse amplitude per injection, and preservation of pituitary function

CJC-1295 with DAC: The Convenience Option

Half-life: ~8 days (via albumin binding)

GH release pattern: Continuous elevation of GH throughout the week — a "GH bleed" — with less pronounced peaks and reduced trough periods

Dosing advantage: Once or twice-weekly injections vs twice-daily injections with MOD GRF. Significantly lower injection burden.

Concerns:

• Reduces GH pulsatility — potentially blunting the physiological advantages of pulsatile release
• Higher water retention compared to MOD GRF (more sustained GH → more sustained IGF-1 → more sodium retention)
• Potential somatotroph desensitization with very long-term use
• Less studied than the pulsatile approach

Best for: Researchers seeking convenience (weekly injection schedule), those already on weekly testosterone protocols who want to add GH support with minimal injection burden

GH Pulse Comparison

The Gold Standard Protocol: MOD GRF 1-29 + Ipamorelin

The combination of MOD GRF 1-29 + Ipamorelin has become the preferred GH research protocol because:

• Complementary mechanisms (GHRH + GHRP): 3-10x larger GH pulse than either alone
• Ipamorelin's selectivity (no cortisol/prolactin): clean GH-only effect
• Pulsatile delivery (1-2 injections/day): physiological GH pattern
• Minimal side effects compared to GHRP-6 or hexarelin-based stacks

Protocol:

• MOD GRF 1-29: 100-300mcg SubQ
• Ipamorelin: 100-300mcg SubQ
• Inject both simultaneously, 30-60 minutes before sleep (and optionally after exercise)
• Reconstitute each separately in bacteriostatic water; draw both into same syringe for injection

Frequently Asked Questions

Q: Can "CJC-1295 without DAC" be purchased as a product? A: "CJC-1295 without DAC" is just another name for Modified GRF 1-29 — they are the same compound. The naming confusion exists because some early research peptide vendors labeled MOD GRF as "CJC-1295 without DAC." The simplified term MOD GRF 1-29 is cleaner. Always verify which compound you have — if there is no mention of DAC, it's MOD GRF.

Q: Is there a way to combine the convenience of CJC-DAC with the pulsatility of MOD GRF? A: Some researchers use CJC-DAC twice weekly (lower frequency) while adding once-daily MOD GRF for additional pulsatile pulses. This hybrid approach hasn't been studied systematically but represents a pragmatic compromise for researchers who value some pulsatility but can't inject twice daily.

Use the Reconstitution Calculator → /calculators/reconstitution

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions